Collected Works of Terence J. Hamblin


Photo of Terry Hamblin

Dr. Terence J. Hamblin’s co-discovery with Dr. Nicholas Chiorazzi of the clinical significance of unmutated and mutated Ig genes in CLL allowed for the separation of patients into two major clinical groups: indolent clinical course and aggressive clinical course. Dr. Hamblin’s research interests developed out of an early 1972 paper on mononucleosis, which led to a life-long interest in cold agglutinin disease. This led him to VH Ig genes and the discovery of shared idiotypes in cold agglutinin disease. Subsequently, he observed the relationship of unmutated Ig genes to patients with trisomy 12 and the relationship of mutated Ig genes to patients with 13q14 deletion. This observation led to the conclusion that unmutated Ig genes in CLL are associated with a more aggressive clinical behavior in terms of time to treatment and overall survival. The role of CD38 expression led to the further observation of occasional discordance between these biomarkers.

A set of video clips in which Dr. Hamblin discusses the development of his research may be found in this archive.

Collected Works














  • Mufti GJ, Hamblin TJ, Gordon J. Melphalan-induced pulmonary fibrosis in osteosclerotic myeloma. Acta Haematol. 1983;69(2):140-1.
  • Mufti GJ, Hamblin TJ, Lee-Potter JP. The aplasia-leukaemia syndrome. Aplastic anaemia followed by dyserythropoiesis, myeloproliferative syndrome and acute myeloid leukaemia. Acta Haematol. 1983;69(5):349-52.
  • Mallya RK, Young BJ, Pepys MB, Hamblin TJ, Mace BE, Hamilton EB. Anti-keratin antibodies in rheumatoid arthritis: frequency and correlation with other features of the disease. Clin Exp Immunol. 1983 Jan;51(1):17-20.
  • Hamblin TJ, Smith DS. Long-term plasma-exchange. (A feasible treatment in systemic lupus erythematosus and other diseases). Ric Clin Lab. 1983 Jan-Mar;13(1):95-102.
  • Grant CJ, Hamblin TJ, Smith DS, Wellstead L. Plasmapheresis in Rh hemolytic disease: the danger of amniocentesis. Int J Artif Organs. 1983 Mar;6(2):83-6.
  • Mufti GJ, Hamblin TJ, Clein GP, Race C. Coexistent myelodysplasia and plasma cell neoplasia. Br J Haematol. 1983 May;54(1):91-6.
  • Hamblin TJ. Blood counts and economics. Br Med J (Clin Res Ed). 1983 Jun 18;286(6382):1918-9.
  • Hamblin TJ, Hussain J, Akbar AN, Tang YC, Smith JL, Jones DB. Immunological reason for chronic ill health after infectious mononucleosis. Br Med J (Clin Res Ed). 1983 Jul 9;287(6385):85-8.
  • Hatty S, Mufti GJ, Hamblin TJ. Exercise-induced urticaria and angio-oedema with relief from cromoglycate insufflation. Postgrad Med J. 1983 Sep;59(695):586-7.
  • Mufti GJ, Hamblin TJ, Oscier DG, Johnson S. Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations. Blood. 1983 Nov;62(5):1142-6.
  • Mufti GJ, Oscier DG, Hamblin TJ, Bell AJ. Low doses of cytarabine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. N Engl J Med. 1983 Dec 29;309(26):1653-4.






  • Gregg E, Hamblin T, Smith J, Stevenson F. Heterogeneity in neoplastic cell populations in chronic lymphocytic leukaemia defined by immunoglobulin expression and secretion in vitro. Leuk Res. 1988;12(2):123-7.
  • Gow J, Hughes D, Farr C, Hamblin T, Oscier D, Brown R, Padua RA. Activation of Ha-ras in human chronic granulocytic and chronic myelomonocytic leukaemia. Leuk Res. 1988;12(10):805-10.
  • Stevenson FK, Smith GJ, North J, Glennie MG, Hamblin TJ. Use of a cross reacting anti-idiotype to identify normal counterparts of neoplastic cells. Nouv Rev Fr Hematol. 1988;30(5-6):299-300.
  • Oscier DG, Fitchett M, Hamblin TJ. Chromosomal abnormalities in B-CLL. Nouv Rev Fr Hematol. 1988;30(5-6):397-8.
  • Stevenson GT, Glennie MJ, Hamblin TJ, Lane AC, Stevenson FK. Problems and prospects in the use of lymphoma idiotypes as therapeutic targets. Int J Cancer Suppl. 1988;3:9-12.
  • Bell AJ, Figes A, Oscier DG, Hamblin TJ. Relapse after autografting with peripheral blood stem cells. Lancet. 1988 Jan 23;1(8578):190.  
  • Worsley A, Oscier DG, Stevens J, Darlow S, Figes A, Mufti GJ, Hamblin TJ. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br J Haematol. 1988 Jan;68(1):17-21.
  • Bell AJ, Figes A, Oscier DG, Hamblin TJ. Immunological reconstitution after bone marrow transplantation with Campath-1 treated bone marrow. Bone Marrow Transplant. 1988 May;3(3):239-41.
  • Smith JL, Oscier DG, Haegert DG, Jones DB, Howell M, Hodges E, Stevenson FK, Hamblin TJ. CD3+ CD8+ T cell lymphocytosis masking B cell leukaemia. J Clin Pathol. 1988 Jul;41(7):746-52.
  • George AJ, Folkard SG, Hamblin TJ, Stevenson FK. Idiotypic vaccination as a treatment for a B cell lymphoma. J Immunol. 1988 Sep 15;141(6):2168-74.
  • Dearman RJ, Stevenson FK, Wrightham M, Hamblin TJ, Glennie MJ, Stevenson GT. Lymphokine-activated killer cells from normal and lymphoma subjects are cytotoxic for cells coated with antibody derivatives displaying human Fc gamma. Blood. 1988 Dec;72(6):1985-91.


  • Hamblin TJ. Modifications of monoclonal antibody for immunotherapy. Immunotherapy of Disease. Dordrecht; Boston: Kluwer Academic Publishers; 1989: 143-166.
  • Hamblin TJ. Clinical parameters for evaluating biological response modifier therapy. Eur J Cancer Clin Oncol. 1989;25(Suppl 3):S7-9.
  • Oscier DG, Worsley A, Darlow S, Figes A, Williams JD, Hamblin TJ. Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score. Leuk Res. 1989;13(9):833-9.
  • Copplestone JA, Smith AG, Osmond C, Oscier DG, Hamblin TJ. Treatment of acute myeloid leukemia in the elderly: a clinical dilemma. Hematol Oncol. 1989 Jan-Feb;7(1):53-9.
  • Stevenson FK, Smith GJ, North J, Hamblin TJ, Glennie MJ. Identification of normal B-cell counterparts of neoplastic cells which secrete cold agglutinins of anti-I and anti-i specificity. Br J Haematol. 1989 May;72(1):9-15.
  • Hamblin TJ, Inzani V, Sadullah S, Stevenson FK, Williamson P, van der Plas J, Palmer P, Franks CR. A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma. Cancer Treat Rev. 1989 Jun;16(Suppl A):163-7.
  • Oscier DG, Worsley A, Hamblin TJ, Mafti GJ. Treatment of chronic myelomonocytic leukemia with low dose etoposide. Br J Haematol. 1989 Jul;72(3):468-71.
  • Williamson PJ, Oscier DG, Mufti GJ, Hamblin TJ. Pyogenic abscesses in the myelodysplastic syndrome. BMJ. 1989 Aug 5;299(6695):375-6.
  • Binet JL, Catovsky D, Chastang C, Dighiero G, Fooks J, Galton DAG, Gates A, Hamblin TJ, Han T, Hansen MM, Keating MJ, Montserrat E, Pangalis GA, Polliack A, Rai KR, Richards S, International Workshop on CLL. Prognostic features of early chronic lymphocytic leukaemia. Lancet. 1989 Oct 21;334(8669):968-969.


  • Hamblin TJ. Ex vivo activation and retransfusion of white blood cells. The immunotherapy of cancer. Curr Stud Hematol Blood Transfus. 1990;(57):249-66.
  • Hamblin T. The future in apheresis: the cell revisited. Prog Clin Biol Res. 1990;337:xlv-xlvii.
  • Hamblin TJ. Induction and expansion of LAK cells for cancer immunotherapy. Prog Clin Biol Res. 1990;337:551-3.
  • Hamblin TJ. Interleukin 2. BMJ. 1990 Feb 3;300(6720):275-6.
  • Hamblin T. Reconstitution of interleukin-2 with albumin for infusion. Lancet. 1990 Jul 28;336(8709):251.
  • Hamblin TJ. Endothelins. BMJ. 1990 Sep 22;301(6752):568.
  • Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Fitchett M. Prognostic factors in stage AO B-cell chronic lymphocytic leukaemia. Br J Haematol. 1990 Nov;76(3):348-51.
  • Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Lambert R, Fitchett M. Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1990 Nov;76(3):352-8.
  • Smith GJ, Spellerberg MB, North J, Hamblin TJ, Stevenson FK. Isolation and EBV-transformation of a minor population of normal human tonsillar B cells bearing a cold agglutinin-associated idiotope. J Autoimmun. 1990 Dec;3(6):759-71.


  • Catovsky D, Richards S, Fooks J, Hamblin TJ. CLL Trials in the United Kingdom the Medical Research Council CLL Trials 1, 2 and 3. Leuk Lymphoma. 1991;5(Suppl 1):105-11.
  • Hamblin TJ. E. Donnall Thomas, M.D. Nobel laureate 1990. Leuk Res. 1991;15(2-3):71.
  • Dyke RJ, McBride H, George AJ, Hamblin TJ, Stevenson FK. Idiotypic vaccination against B-cell lymphoma leads to dormant tumour. Cell Immunol. 1991 Jan;132(1):70-83.
  • Stevenson FK, Bell AJ, Cusack R, Hamblin TJ, Slade CJ, Spellerberg MB, Stevenson GT. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood. 1991 Mar 1;77(5):1071-9.
  • Williamson PJ, Oscier DG, Bell AJ, Hamblin TJ. Red cell aplasia in myelodysplastic syndrome. J Clin Pathol. 1991 May;44(5):431-2.
  • Pascual V, Victor K, Lelsz D, Spellerberg MB, Hamblin TJ, Thompson KM, Randen I, Natvig J, Capra JD, Stevenson FK. Nucleotide sequence analysis of the V regions of two IgM cold agglutinins. Evidence that the VH4-21 gene segment is responsible for the major cross-reactive idiotype. J Immunol. 1991 Jun 15;146(12):4385-91.
  • Hamblin TJ. Interleukin-2 for anti-cancer therapy. Compr Ther. 1991 Dec;17(12):35-8.



  • Hamblin T. Recent advances in the management of myelodysplastic syndromes. Hematol Oncol. 1993;11(Suppl 1):27-31.
  • King CA, Wills MR, Hamblin TJ, Stevenson FK. Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells. Cell Immunol. 1993 Apr 1;147(2):411-24.
  • Stevenson FK, Spellerberg MB, Treasure J, Chapman CJ, Silberstein LE, Hamblin TJ, Jones DB. Differential usage of an Ig heavy chain variable region gene by human B-cell tumors. Blood. 1993 Jul 1;82(1):224-30.
  • Chapman CJ, Spellerberg MB, Smith GA, Carter SJ, Hamblin TJ, Stevenson FK. Autoanti-red cell antibodies synthesized by patients with infectious mononucleosis utilize the VH4-21 gene segment. J Immunol. 1993 Jul 15;151(2):1051-61.
  • Hawkins RE, Winter G, Hamblin TJ, Stevenson FK, Russell SJ. A genetic approach to idiotypic vaccination. J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):273-8.
  • Kruger A, Sadullah S, Chapman R, Hodges E, Mould S, Hamblin TJ, Oscier DG. Use of a retinoblastoma gene probe to investigate clonality in Richter’s syndrome. Leukemia. 1993 Nov;7(11):1891-5.
  • Hamblin TJ, Sadullah S, Williamson P, Stevenson J, Oskam R, Palmer P, Franks CR. A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. Br J Cancer. 1993 Dec;68(6):1186-9.
  • Stevenson FK, Longhurst C, Chapman CJ, Ehrenstein M, Spellerberg MB, Hamblin TJ, Ravirajan CT, Latchman D, Isenberg D. Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus. J Autoimmun. 1993 Dec;6(6):809-25.


  • Stevenson FK, Spellerberg MB, Treasure J, Chapman CJ, Silberstein LE, Hamblin TJ, Jones DB. Differential usage of an autoantibody-associated VH gene by human B-cell tumors. In Zouali M, Ed. Autoimmunity: Experimental Aspects. NATO ASI Series (Series H: Cell Biology), vol 80. Berlin, Germany: Springer-Verlag; 1994: 163-172.
  • Stevenson GT, Bell AJ, Evans TR, French RR, Glennie MJ, Hamblin TJ, Kan KS, Mead GM. Mechanisms in removal of tumor by antibody. Cell Biophys. 1994;24-25:45-50.
  • McCullen M, Vyas SK, Winwood PJ, Loehry CA, Parham DM, Hamblin T. Long-term survival associated with metastatic small cell carcinoma of the esophagus treated by chemotherapy, autologous bone marrow transplantation, and adjuvant radiation therapy. Cancer. 1994 Jan 1;73(1):1-4.;2-e
  • Zhu D, Hawkins RE, Hamblin TJ, Stevenson FK. Clonal history of a human follicular lymphoma as revealed in the immunoglobulin variable region genes. Br J Haematol. 1994 Mar;86(3):505-12.
  • Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, Stevenson FK. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood. 1994 Jun 1;83(11):3279-88.
  • Sahota S, Hamblin T, Oscier DG, Stevenson FK. Assessment of the role of clonogenic B lymphocytes in the pathogenesis of multiple myeloma. Leukemia. 1994 Aug;8(8):1285-9.
  • Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994 Aug;87(4):743-5.
  • Bennett JM, Hamblin TJ. Medical bioresearch and scientific integrity. Leuk Res. 1994 Oct;18(10):725-6.
  • Hamblin TJ. Pseudo-myelodysplastic syndrome with t(8;21). Leuk Res. 1994 Oct;18(10):767-8.


  • Stevenson FK, Spellerberg MB, Chapman CJ, Hamblin TJ. Differential usage of an autoantibody-associated VH gene, VH4-21, by human B-cell tumors. Leuk Lymphoma. 1995 Feb;16(5-6):379-84.
  • Chapman CJ, Spellerberg MB, Hamblin TJ, Stevenson FK. Pattern of usage of the VH4-21 gene by B lymphocytes in a patient with EBV infection indicates ongoing mutation and class switching. Mol Immunol. 1995 Apr;32(5):347-53.
  • Hamblin TJ. 1st International Conference on Reversal of Multidrug Resistance in Cancer. St. Gallen, Switzerland, 1-3 September 1994. Leuk Res. 1995 Jun;19(6):427-8.
  • Allan NC, Richards SM, Shepherd PCA, Burnett AK, Al-Ismail S, Barkhan P, Barrett A, Beard MEJ, Bellingham AJ, Black AJ, Bridges JM, Bunch C, Carey P, Catovsky D, Cawley JC, Child JA, Clark R, Cuthbert M, Cuzick JM, Dastgir M, Delamore IW, Dodd NH, Durie B, Durrant J, Franklin IM, Galton DAG, Gates A, Goldman JM, Goldstone AH, Gray R, Hamblin TJ, Hamilton P, Hobbs J, Hoffbrand AV, Hutchinson RM, Jones FGC, Linch D, Littlewood TJ, MacLennan ICM, McCann SR, McDonald GA, McElwain T, Maton-Howarth W, Milligan DW, Mufti GJ, Murphy B, Newland AC, Peto R, Powles R, Prentice AG, Prentice HG, Rajman A, Rees JKH, Roath OS, Roberts BE, Schey SA, Smith A, Stableforth PJ, Tansey PJ, Temperley I, Varcoe R, Wheatley K, Whittaker JA, Wilson E, Winfield DA, Liu Yin JA. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995 Jun 3;345(8962):1392-7.
  • Hamblin TJ. Disappointments in treating acute leukemia in the elderly. N Engl J Med. 1995 Jun 22;332(25):1712-3.
  • French RR, Hamblin TJ, Bell AJ, Tutt AL, Glennie MJ. Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin. Lancet. 1995 Jul 22;346(8969):223-4.
  • Chapman C, Spellerberg M, Hamblin T, Stevenson F. Pattern of usage of the VH4-21 gene by B lymphocytes in a patient with EBV infection indicates ongoing mutation and class switching. Ann N Y Acad Sci. 1995 Sep 29;764:195-7.
  • Spellerberg M, Chapman C, Hamblin T, Stevenson F. Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene. A possible link between infection and lupus. Ann N Y Acad Sci. 1995 Sep 29;764:427-32.
  • Chapman CJ, Mockridge CI, Spellerberg MB, Isenberg DA, Hamblin TJ, Stevenson FK. Use of a phage expression system to produce Fabs from human autoanti-DNA antibodies encoded by the VH4-21 gene segment. Ann N Y Acad Sci. 1995 Sep 29;764:576-9.
  • Hamblin TJ. Chronic lymphocytic leukaemia–new drugs and management. J R Coll Physicians Lond. 1995 Sep-Oct;29(5):419-21.
  • Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG, Hamon MD, Oscier DG, Hamblin TJ. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol. 1995 Oct;91(2):341-4.


  • Sahota SS, Leo R, Hamblin TJ, Stevenson FK. Ig VH gene mutational patterns indicate different tumor cell status in human myeloma and monoclonal gammopathy of undetermined significance. Blood. 1996 Jan 15;87(2):746-55.
  • Matutes E, Oscier D, Garcia-Marco J, Ellis J, Copplestone A, Gillingham R, Hamblin T, Lens D, Swansbury GJ, Catovsky D. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol. 1996 Feb;92(2):382-8.
  • Hamblin TJ. From dendritic cells to tumour vaccines. Lancet. 1996 Mar 16;347(9003):705-6.
  • Hamblin TJ, Bennett JM. t(8:21) Myelodysplasia. Br J Haematol. 1996 Mar;92(3):766-7.
  • Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol. 1996 Apr;33(2):150-62.
  • French RR, Bell AJ, Hamblin TJ, Tutt AL, Glennie MJ. Response of B-cell lymphoma to a combination of bispecific antibodies and saporin. Leuk Res. 1996 Jul;20(7):607-17.
  • Chapman CJ, Mockridge CI, Hamblin TJ, Stevenson FK. Tracking of the V4-34 (VH4-21) gene in human tonsil reveals clonal isotype switch events and a highly variable degree of somatic hypermutation. Clin Exp Immunol. 1996 Aug;105(2):360-8.


  • Sahota SS, Leo R, Hamblin TJ, Stevenson FK. Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood. 1997 Jan 1;89(1):219-26.
  • Hamblin T. Cytokines to reduce platelet transfusions: non-TPO cytokines. Transfus Sci. 1997 Mar;18(1):121-8.
  • Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 Mar 15;89(6):2079-88.
  • Orchard J, Myint H, Hamblin TJ. A patient with myeloma who still has pure red cell aplasia despite the most intensive immune modulation. Leuk Res. 1997 Apr;21(4):353-4.
  • Myint H, Ross FM, Hall JL, Hamblin TJ. Early transformation to acute myeloblastic leukaemia with the acquisition of inv(16) in Ph positive chronic granulocytic leukaemia. Leuk Res. 1997 May;21(5):473-4.
  • Zhu D, Spellerberg MB, Thompsett A, King CA, Hamblin TJ, Stevenson FK. DNA vaccination as cancer immunotherapy. Biochem Soc Trans. 1997 May;25(2):743-7.
  • Hawkins RE, Russell SJ, Marcus R, Ashworth LJ, Brissnik J, Zhang J, Winter G, Bleehen NM, Shaw MM, Williamson L, Ouwehand W, Stevenson F, Hamblin T, Oscier D, Zhu D, King C, Kumar S, Thompsett A, Stevenson GT. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027. Hum Gene Ther. 1997 Jul 1;8(10):1287-99.
  • Spellerberg MB, Zhu D, Thompsett A, King CA, Hamblin TJ, Stevenson FK. DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J Immunol. 1997 Aug 15;159(4):1885-92.
  • Hamblin TJ. Clinician’s overview of platelet support. Transfus Sci. 1997 Sep;18(3):351-3.
  • Hamblin TJ, Oscier DG. Chronic lymphocytic leukaemia: the nature of the leukaemic cell. Blood Rev. 1997 Sep;11(3):119-28.
  • Oscier DG, Matutes E, Copplestone A, Pickering RM, Chapman R, Gillingham R, Catovsky D, Hamblin TJ. Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br J Haematol. 1997 Sep;98(4):934-9.
  • Hamblin TJ. Trisomy 12 in CLL revisited. Leuk Res. 1997 Nov-Dec;21(11-12):1025-6.


  • Stevenson F, Sahota S, Zhu D, Ottensmeier C, Chapman C, Oscier D, Hamblin T. Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. Immunol Rev. 1998 Apr;162:247-59.
  • Hamblin TJ, Orchard JA, Myint H, Oscier DG. Fludarabine and hemolytic anemia in chronic lymphocytic leukemia. J Clin Oncol. 1998 Sep;16(9):3209-10.
  • Orchard J, Bolam S, Myint H, Oscier DG, Hamblin TJ. In patients with lymphoid tumours recovering from the autoimmune complications of fludarabine, relapse may be triggered by conventional chemotherapy. Br J Haematol. 1998 Sep;102(4):1112-3.
  • Bennett JM, Hamblin TJ. Under-reporting of clinical trials is a well known ‘occupational hazard’. Leuk Res. 1998 Oct;22(10):v-vii, ix.
  • King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med. 1998 Nov;4(11):1281-6.


  • Anderson KC, Hamblin TJ, Traynor A. Management of multiple myeloma today. Semin Hematol. 1999 Jan;36(1 Suppl 3):3-8.
  • Maloney DG, Donovan K, Hamblin TJ. Antibody therapy for treatment of multiple myeloma. Semin Hematol. 1999 Jan;36(1 Suppl 3):30-3.
  • Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol. 1999 Jan;17(1):399-408.
  • CLL Trialists’ Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists’ Collaborative Group. J Natl Cancer Inst. 1999 May 19;91(10):861-8.
  • Stevenson FK, King CA, Spellerberg MB, Zhu D, Rice J, Sahota S, Thompsett A, Radl J, Hamblin TJ. DNA vaccines against haematological malignancies. Haematologica. 1999 Jun;84 Suppl EHA-4:11-3.
  • Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999 Sep 15;94(6):1848-54.
  • Bolam S, Hamblin T. Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia. Drugs Aging. 1999 Dec;15(6):451-60.



  • Hamblin TJ. Autoimmune disease and its management in chronic lymphocytic leukemia. In Cheson B, ed. Chronic Lymphocytic Leukemia. Second edition. New York, NY: Marcel Dekker; 2001: 435-458.
  • Hamblin TJ. Achieving optimal outcomes in chronic lymphocytic leukaemia. Drugs. 2001;61(5):593-611.
  • Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res. 2001;83:81-116.


  • Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2002:193-213.
  • Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, Oscier DG. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002 Feb 1;99(3):1023-9.
  • Zhu D, McCarthy H, Ottensmeier CH, Johnson P, Hamblin TJ, Stevenson FK. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood. 2002 Apr 1;99(7):2562-8.
  • Hamblin T. Chronic lymphocytic leukaemia: one disease or two? Ann Hematol. 2002 Jun;81(6):299-303. Epub 2002 May 18.
  • Hamblin TJ. UK CLL Forum, London, 25th October 2001. Leuk Res. 2002 Jun;26(6):607-9.
  • Hamblin T. Waiting in the NHS. J R Soc Med. 2002 Jul;95(7):377.
  • Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, Corcoran MM, Chapman RM, Thomas PW, Copplestone JA, Orchard JA, Hamblin TJ. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002 Aug 15;100(4):1177-84.
  • Sahota SS, Forconi F, Ottensmeier CH, Provan D, Oscier DG, Hamblin TJ, Stevenson FK. Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. Blood. 2002 Aug 15;100(4):1505-7.
  • Cragg MS, Chan HT, Fox MD, Tutt A, Smith A, Oscier DG, Hamblin TJ, Glennie MJ. The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis. Blood. 2002 Nov 1;100(9):3068-76.
  • Hamblin T. Is chronic lymphocytic leukemia one disease? Haematologica. 2002 Dec;87(12):1235-8.
  • Potter KN, Mockridge CI, Rahman A, Buchan S, Hamblin T, Davidson B, Isenberg DA, Stevenson FK. Disturbances in peripheral blood B cell subpopulations in autoimmune patients. Lupus. 2002 Dec 1;11(12):872-7.


  • Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003 Feb 1;101(3):1087-93. Epub 2002 Sep 26.
  • Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003 Jun 15;101(12):4944-51. Epub 2003 Feb 20.
  • Clark RH, Stinchcombe JC, Day A, Blott E, Booth S, Bossi G, Hamblin T, Davies EG, Griffiths GM. Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol. 2003 Nov;4(11):1111-20. Epub 2003 Oct 19.
  • McCarthy H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Br J Haematol. 2003 Dec;123(5):770-81.


  • Hamblin TJ. The Heterogeneous Origin of the B-CLL Cell. In Faguet GB, ed. Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Totowa, NJ: Humana Press Inc. 2004; 95-107.
  • Hamblin TJ. Autoimmune and hypersplenic cytopenias. In Faguet GB, ed. Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Totowa, NJ: Humana Press Inc. 2004; 361-376.
  • Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM, Oscier DG. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004 Jan 10;363(9403):105-11.
  • Mockridge CI, Rahman A, Buchan S, Hamblin T, Isenberg DA, Stevenson FK, Potter KN. Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. Autoimmunity. 2004 Feb;37(1):9-15.
  • Hamblin TJ. Predicting Progression–ZAP-70 in CLL. N Engl J Med. 2004 Aug 26;351(9):856-7.


  • Hamblin TJ. Chronic lymphocytic leukaemia: clinical translations of biological features. Curr Top Microbiol Immunol. 2005;294:165-85.
  • Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica. 2005 Mar;90(3):391-9.
  • Hamblin TJ. The management of anemia in the myelodysplastic syndrome. Leuk Res. 2005 Oct;29(10):1101-2. Epub 2005 Apr 9.
  • Hamblin TJ. Richter’s syndrome–the downside of fludarabine? Leuk Res. 2005 Oct;29(10):1103-4. Epub 2005 Apr 9.
  • Porakishvili N, Kulikova N, Jewell AP, Youinou PY, Yong K, Nathwani A, Heelan B, Duke V, Hamblin TJ, Wallace P, Ely P, Clark EA, Lydyard PM. Differential expression of CD 180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol. 2005 Nov;131(3):313-9.
  • Hamblin AD, Hamblin TJ. Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia. Expert Opin Ther Targets. 2005 Dec;9(6):1165-78.



  • Hamblin TJ. Aggressive transformation and paraneoplastic complications of chronic lymphocytic leukemia. In Sekeres MA, Kalaycio ME, Bolwell BJ, eds. Clinical Malignant Hematology. New York, NY: McGraw Hill; 2007:251-264.
  • Hoffbrand AV, Hamblin TJ. Is “leukemia” an appropriate label for all patients who meet the diagnostic criteria of chronic lymphocytic leukemia? Leuk Res. 2007 Mar;31(3):273-5. Epub 2006 Aug 22.
  • Hamblin T. Open forum–Are myelodysplastic syndromes cancer? Response to Dr. Steensma. Leuk Res. 2007 Mar;31(3):412-3. Epub 2006 Sep 28.
  • Hamblin TJ. Long-lasting response of therapy-resistant viral warts to treatment with interleukin-2 in a patient with chronic lymphocytic leukemia (CLL) and profound immunodeficiency. Leuk Res. 2007 Mar;31(3):413-4. Epub 2006 Sep 22.
  • Hamblin TJ. ZAP-70 levels do change in CLL but not very often. Leuk Lymphoma. 2007 Jun;48(6):1059-60.
  • Catovsky D, Richards S, Matutes E, Oscier D, Dyer M, Bezares RF, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P; UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007 Jul 21;370(9583):230-239.
  • Chacko J, Pennell DJ, Tanner MA, Hamblin TJ, Wonke B, Levy T, Thomas PW, Killick SB. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol. 2007 Sep;138(5):587-93. Epub 2007 Jul 4.
  • Hamblin TJ. Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2007 Sep;20(3):455-68.


  • Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia – long-term follow up of patients with different percentages of mutations. Br J Haematol. 2008 Feb;140(3):320-3. Epub 2007 Dec 5.
  • Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T, Catovsky D; UK National Cancer Research Institute (NCRI); Haematological Oncology Clinical Studies Group; NCRI CLL Working Group. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood. 2008 Feb 15;111(4):1820-6. Epub 2007 Nov 30.
  • Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008 Mar 22;371(9617):1017-29.
  • Hamblin TJ. Have we been wrong about ionizing radiation and chronic lymphocytic leukemia? Leuk Res. 2008 Apr;32(4):523-5. Epub 2007 Oct 29.
  • Patten PE, Buggins AG, Richards J, Wotherspoon A, Salisbury J, Mufti GJ, Hamblin TJ, Devereux S. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood. 2008 May 15;111(10):5173-81. Epub 2008 Mar 7.
  • Hamblin TJ. Ligandless receptors find a role. Blood. 2008 Jul 1;112(1):2-3.
  • Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008;87:49-62. Epub 2008 Aug 27.
  • Hamblin TJ. Complementary medicine . Inconsistency over payment. BMJ. 2008 Nov 3;337:a2388.





  • Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012 May 10;30(14):1647-55. Epub 2012 Apr 9.

Page last updated on January 3, 2020.

%d bloggers like this: